Health Net Cetuximab Coverage & Prior Auth Update

Coverage Criteria for Cetuximab (Erbitux)

Initial Therapy — HNSCC

Initial approval — Head and Neck Squamous Cell Carcinoma (HNSCC): Covered when ALL of the following are met

HNSCC initial: 1) Diagnosis of head and neck squamous cell carcinoma (see Appendix D for subtypes); 2) Prescribed by or in consultation with an oncologist; 3) Member is age >= 18 years; 4) Disease is advanced, recurrent, unresectable, or metastatic; 5) Prescribed as either: (a) in combination with platinum-based therapy (e.g., cisplatin or carboplatin), pembrolizumab (Keytruda), nivolumab (Opdivo), paclitaxel, or docetaxel (if cisplatin-ineligible) OR (b) as a single agent; 6) Dose does not exceed an initial 400 mg/m2 loading dose followed by 250 mg/m2 weekly OR does not exceed 500 mg every 2 weeks (biweekly option); 7) Prescribed regimen must be FDA‑approved or recommended by NCCN; for off‑label uses prescriber must submit supporting evidence (practice guidelines or peer‑reviewed literature).

See Appendix D for HNSCC subtypes; prior authorization may be required for combination agents.

HNSCC operational notes: Prescriber must document indication, prior therapies and rationale for combination or single‑agent use; dosing must follow the listed limits or be supported by guidelines/literature.

Approval duration typically 6 months for initial therapy per policy.

Initial Therapy — Colorectal Cancer

Initial approval — Colorectal Cancer (CRC): Covered when ALL of the following are met

CRC initial: 1) Diagnosis of advanced, unresectable, or metastatic colorectal cancer; 2) Prescribed by or in consultation with an oncologist; 3) Member is age >= 18 years; 4) Tumor molecular and clinical criteria met, including but not limited to: KRAS/NRAS/BRAF status or other specified mutations (e.g., KRAS G12C, BRAF V600E, dMMR/MSI‑H, POLE) as applicable to the requested regimen; 5) For dMMR/MSI‑H or POLE mutation positive tumors: member is ineligible for or has progressed on checkpoint inhibitor immunotherapy; 6) Prescribed as one of the following as applicable: single agent OR in combination with FOLFIRI, FOLFOX, CapeOX, or irinotecan (as specified — e.g., irinotecan following prior therapy) OR, if BRAF V600E mutation positive, in combination with encorafenib (Braftovi) following prior therapy; 7) For colon cancer that is KRAS/NRAS/BRAF wild‑type with unresectable synchronous liver and/or lung metastases: disease must be left‑sided only (see Appendix E); 8) Dose does not exceed an initial 400 mg/m2 loading dose followed by 250 mg/m2 weekly OR does not exceed 500 mg every 2 weeks (biweekly option); 9) Prescribed regimen must be FDA‑approved or recommended by NCCN; off‑label uses require supporting evidence from guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Approval duration: 6 months.

Initial Therapy — Select Off-Label Indications

Off‑label coverage groups (examples): Covered when ALL criteria for each listed off‑label indication are met

NSCLC (off‑label): 1) Diagnosis of recurrent, advanced, or metastatic non‑small cell lung cancer; 2) Prescribed by or in consultation with an oncologist; 3) Member is age >= 18 years; 4) Tumor harbors specified sensitizing EGFR mutations (e.g., exon 19 deletion, exon 21 L858R, S768I, L861Q, G719X) OR tumor is T790M positive with progression on prior EGFR TKI as appropriate; 5) Prescribed in combination with indicated agents (e.g., afatinib/Gilotrif) or as subsequent therapy per guideline pathways; 6) Dose is within FDA maximum limits for any FDA‑approved indication or is supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence).

Approval duration: 6 months.

Penile cancer (off‑label): 1) Diagnosis of metastatic or recurrent penile cancer; 2) Prescribed by or in consultation with an oncologist; 3) Member is age >= 18 years; 4) Prescribed as subsequent‑line systemic therapy as a single agent; 5) Dose is within FDA maximum limits or supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence); 6) Prescribed regimen must be FDA‑approved or recommended by NCCN.

Approval duration: 6 months.

Squamous cell skin cancer (off‑label):

Continuation Therapy

Continued therapy: Covered when ALL of the following are met

Continued therapy: 1) Member is currently receiving cetuximab via the benefit, or documentation supports at least 30 days of prior cetuximab therapy for a covered indication; 2) Member is responding positively to therapy (clinical response documented); 3) If request is for a dose increase: (a) for HNSCC or CRC the new dose does not exceed 250 mg/m2 weekly or 500 mg every 2 weeks, OR (b) the new dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

Approval duration: 12 months.

Selected updated coverage pathways

Coverage and use are aligned to FDA approvals and NCCN recommendations with molecular and clinical qualifiers.

CRC BRAF V600E: Cetuximab coverage allowed in combination with encorafenib (Braftovi) for adult patients with metastatic colorectal cancer with a BRAF V600E mutation per FDA/NCCN pathways; use follows prior therapy requirements as specified in the CRC criteria.mutation positive

This reflects the updated FDA approval for the encorafenib plus cetuximab combination.

CRC left‑sided wild‑type: For colon cancer that is KRAS/NRAS/BRAF wild‑type, cetuximab coverage is limited to left‑sided disease in the setting of unresectable synchronous liver and/or lung metastases (see Appendix E for rationale).left‑sided

Applies only to the specified metastatic setting per NCCN alignment.

HNSCC unresectable combinations: Coverage for HNSCC includes unresectable disease and allows combinations with agents such as nivolumab (Opdivo), pembrolizumab (Keytruda), platinum‑based therapy, paclitaxel, or docetaxel per NCCN updates; the previously required 5‑FU combination was removed.

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy for the member's line of business: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid). If the requested use involves formulary or non‑formulary status considerations, follow the referenced line‑of‑business coverage and non‑formulary policies listed in section F of this policy.

Per the most recent NCCN updates incorporated into this policy, the previously listed basal cell carcinoma indication has been removed and is no longer an authorized indication for cetuximab under this document.

Requests for cetuximab for non‑FDA (off‑label) indications must include supporting clinical documentation per the off‑label use policies referenced above. Specifically, providers should submit office chart notes, pathology and molecular testing results (e.g., KRAS/NRAS/BRAF status when relevant), prior therapy history, and literature or guideline references that demonstrate efficacy and safety consistent with the applicable off‑label use policy before authorization can be granted.

Coding presented in this policy (for example, J9055 for cetuximab 10 mg) is for informational purposes only. Inclusion or exclusion of any code does not guarantee coverage; providers must ensure claims are submitted using current professional coding guidance and that the clinical request meets the policy's medical necessity criteria and documentation requirements.

Initial Therapy — Indication-Specific Criteria

Initial Therapy — aggregated initial therapy criteria per indication groups

Initial therapy criteria per indication groups

Initial — general: 1) Prescribed by or in consultation with an oncologist; 2) Member is age >= 18 years; 3) Disease stage/setting appropriate for the requested indication (see indication‑specific criteria); 4) Dosing within listed limits (initial 400 mg/m2 then 250 mg/m2 weekly OR 500 mg every 2 weeks biweekly option) unless supported by guidelines or literature; 5) Prescribed regimen must be FDA‑approved or recommended by NCCN; off‑label uses require supporting evidence (prescriber must submit).

Initial approval duration typically 6 months for most indications.

Indication groups: Follow the indication‑specific initial criteria for HNSCC, CRC, NSCLC (selected molecular subsets), penile cancer, and squamous cell skin cancer as listed in the policy; each indication requires the listed tumor/molecular qualifiers, prior therapy requirements, and dosing limits.

See respective initial therapy blocks for full detail.

Initial dosing regimens as specified in prescribing information

Criteria for Continued Therapy

Continuation Therapy — criteria for ongoing cetuximab

Criteria for continuation of cetuximab

Continuation nodes: 1) Member currently receiving cetuximab via the benefit or documentation supports at least 30 days of prior therapy for a covered indication; 2) Documented clinical response or clinical benefit while on therapy; 3) If a dose increase is requested, the new dose must not exceed 250 mg/m2 weekly or 500 mg every 2 weeks for HNSCC or CRC, unless the increase is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

Approval duration for continued therapy: 12 months.

Dosing schedules — weekly and biweekly continuation options per updated prescribing information

Continuation dosing options reflect weekly and biweekly schedules as per updated prescribing information.

Maintenance dosing: Weekly option: initial 400 mg/m2 IV loading dose then 250 mg/m2 IV weekly; Biweekly option: dosing per updated prescribing information (biweekly mg/m2 schema) permitted for maintenance in HNSCC and CRC; selection of schedule should align with prescribing information and clinical judgment.

Coding and Billing

HCPCS CodesHCPCSCovered

J9055

Injection, cetuximab, 10 mg

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for cetuximab (Erbitux) — provider must obtain approval before therapy is initiated and requests must align with the clinical criteria in this policy (diagnosis, prescriber specialty, age, disease stage, mutation status, and combination/sequence therapy requirements).

Prior authorization required for initial and continuation requests
Prior authorization may also be required for some combination agents (e.g., platinum-based therapies, EGFR TKIs, Tagrisso, Gilotrif, Braftovi) — verify PA requirements for concomitant agents

Documentation Required

Required Documentation — provide supporting clinical information

Providers must submit supporting clinical documentation with the prior authorization request — examples include office/consult notes, pathology reports, molecular testing results (e.g., KRAS/NRAS/BRAF, dMMR/MSI, EGFR mutation status), prior treatment history, and lab results. Incomplete documentation may lead to denial or delay.

Key Definitions and Molecular Qualifiers

Left‑sided colon (definition)

DefinitionLeft-sided colon defined as splenic flexure to rectum (applies to cetuximab use in KRAS/NRAS/BRAF wild-type colon cancer with unresectable, synchronous liver and/or lung metastases).

Clinical rationaleNCCN guidance notes patients with right-sided tumors (hepatic flexure through cecum) are unlikely to respond; transverse colon data are lacking.

Scope qualifierLeft-sided requirement applies to the specified metastatic setting (unresectable, synchronous liver and/or lung metastases) per Appendix E.

dMMR / MSI‑High (definition)

TermDeficient mismatch repair / microsatellite instability‑high (dMMR/MSI‑H).

Source contextListed in abbreviations/appendix as 'dMMR/MSI‑H: deficient mismatch repair/microsatellite instability‑high'.

Step Therapy and Therapeutic Alternatives

Therapeutic alternative	Typical setting / notes
Modified FOLFOX6 (oxaliplatin + folinic acid + 5-FU)
CRC: common first‑line backbone; dosing per Appendix B and may be required prior to cetuximab depending on formulary/line‑of‑business
FOLFIRI (irinotecan + leucovorin + 5‑FU)
CRC: alternative systemic regimen for metastatic CRC; listed as a therapeutic alternative in Appendix B
FOLFOXIRI (5‑FU + leucovorin + oxaliplatin + irinotecan)
CRC: intensive combination option (Appendix B); may be considered prior to cetuximab based on clinical scenario
CapeOX (capecitabine + oxaliplatin)
CRC: listed in Appendix B (CapeOX) and noted in policy updates as an added combination option for CRC
Checkpoint inhibitor therapies (pembrolizumab, nivolumab ± ipilimumab)
CRC/HNSCC/Squamous cell skin cancer: immune checkpoint inhibitors listed as alternatives where indicated; may be preferred for dMMR/MSI‑H or as per NCCN guidance
Platinum‑based regimens (cisplatin or carboplatin ± 5‑FU)
HNSCC: standard combination chemotherapy options listed in Appendix B (e.g., cisplatin or carboplatin with 5‑FU); may be required prior to cetuximab per LOB formulary
Targeted TKIs (e.g., afatinib, gefitinib, osimertinib, erlotinib)
NSCLC and select molecular subtypes: listed in Appendix B as therapeutic alternatives for relevant off‑label pathways; use per molecular eligibility

Requirement	Applies to
Trial of generic equivalent required when a generic formulation is available
Brand‑name cetuximab requests (applies to brand requests where a generic equivalent exists)

Quantity Limits and Product Presentations

Cetuximab — product presentation and quantity notes

Vial presentationsSingle‑dose vials: 100 mg/50 mL and 200 mg/100 mL.

HCPCS unitHCPCS code for cetuximab: J9055 (Injection, cetuximab, 10 mg) — dosing and billing should reference vial strengths above.

Quantity limit infoPolicy lists product availability and vial sizes; no specific numeric quantity limit was provided in the document's quantity limits section.

AdministrationCetuximab is supplied in single‑dose vials for IV infusion in an appropriate infusion center setting.

Site of Care and Administration

Note

Infusion center administration — IV in appropriate setting

Administer cetuximab intravenously in an appropriate infusion setting (infusion center) per standard oncology practice; the agent is supplied as single‑dose vials and should be handled by trained infusion staff.

Ensure administration occurs in an appropriate infusion center setting.
Prepare and handle single‑dose vials (100 mg, 200 mg) according to product labeling and facility protocols.

Background and Clinical Context

Cetuximab (Erbitux) is a monoclonal antibody that antagonizes the epidermal growth factor receptor (EGFR) and is used primarily in certain head and neck squamous cell carcinomas and colorectal cancers. Its clinical benefit is linked to tumor molecular characteristics (for colorectal cancer, for example, KRAS/NRAS/BRAF mutation status and tumor sidedness influence appropriate use). Dosing follows prescribing information with typical initial regimens of a 400 mg IV loading dose followed by 250 mg/m2 weekly, and biweekly dosing options have been added per updated labeling; single‑dose vial presentations are available in 100 mg and 200 mg strengths.

OpenPayer

Clinical Policy: Cetuximab (Erbitux)

Coverage Criteria for Cetuximab (Erbitux)

Initial Therapy — Indication-Specific Criteria

Criteria for Continued Therapy

Coding and Billing

Provider Actions, Prior Authorization, and Documentation

Key Definitions and Molecular Qualifiers

Step Therapy and Therapeutic Alternatives

Quantity Limits and Product Presentations

Site of Care and Administration

Background and Clinical Context